ChristopherHaekangChayMD

Oncology • Asheville, NC

Physician

Join to view full profile

Dr. Chay is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Chay's full profile

Already have an account?

Office
551 Brevard Road
Asheville, NC 28806
Phone+1 828-212-7021

Fax+1 828-349-0161
Is this information wrong?

Education & Training

University of Michigan Health SystemFellowship, Hematology and Medical Oncology, 1999 - 2002
University of North Carolina HospitalsResidency, Internal Medicine, 1996 - 1999
University of North Carolina at Chapel Hill School of MedicineClass of 1996

Certifications & Licensure

NC State Medical License 1996 - 2024
MI State Medical License 1998 - 2003
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Start of enrollment: 2009 Nov 01
Active, not recruiting
Phase 3
S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride Start of enrollment: 2011 Nov 15
Completed
S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy Start of enrollment: 2013 May 15
Completed
Phase 3
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Active, not recruiting
Phase 3
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Active, not recruiting
Phase 3
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Start of enrollment: 2014 Feb 01
Completed
Phase 2
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) Start of enrollment: 2015 Jun 26
Completed
Phase 1, Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2021 Aug 09
Recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

3 citations
BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma.
Toby A Eyre, Nirav N Shah, Martin Dreyling, Wojciech Jurczak, Yucai Wang, Chan Y Cheah, Yuqin Song, Mitul Gandhi, Christopher Chay, Jeff Sharman, David J Andorsky, Han...> ;Future Oncology. 2022 Nov 1
34 citations
A Community-Based Multicenter Trial of Pharmacokinetically Guided 5-Fluorouracil Dosing for Personalized Colorectal Cancer Therapy
Jai N. Patel, Bert H. O'Neil, Allison M. Deal, Joseph G. Ibrahim, Gary Bradley Sherrill, Oludamilola Olajide, Prashanti Atluri, John J. Inzerillo, Christopher H. Chay,...> ;The Oncologist. 2014 Sep 1
7 citations
Antimetastatic drugs in prostate cancer
Christopher H. Chay, Carlton C. Cooper, Beth A. Hellerstedt, Kenneth J. Pienta> ;Clinical Prostate Cancer. 2002 Jun 1
23 citations
Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma
David Smith, Christopher H. Chay, Rodney L. Dunn, Judith Fardig, Peg Esper, Karin B. Olson, Kenneth J. Pienta> ;Cancer. 2003 Jul 15
141 citations
Stromal factors involved in prostate carcinoma metastasis to bone
Carlton R. Cooper, Christopher H. Chay, James D. Gendernalik, Hyung-Lae Lee, Jasmine Bhatia, Russell S. Taichman, Laurie K. McCauley, Evan T. Keller, Kenneth J. Pienta> ;Cancer. 2003 Feb 1
78 citations
A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines.
Christopher H. Chay, Carlton R. Cooper, James D. Gendernalik, Saravana M. Dhanasekaran, Arul M. Chinnaiyan, Mark A. Rubin, Alvin H. Schmaier, Kenneth J. Pienta> ;Urology. 2002 Nov 1
134 citations
The role of alpha(v)beta(3) in prostate cancer progression.
Carlton R. Cooper, Christopher H. Chay, Kenneth J. Pienta> ;Neoplasia. 2002 May 1
1 citations
New discoveries in prostate cancer biology and treatment. 5-9 December 2001, Naples, Florida, USA.
Carlton R. Cooper, Christopher H. Chay, Kenneth J. Pienta> ;Expert Opinion on Therapeutic Targets. 2002 Feb 1
34 citations
Adjuvant and neoadjuvant therapy in prostate cancer
Christopher H. Chay, David Smith> ;Seminars in Oncology. 2001 Feb 1
8 citations
Evidence for lectin signaling to the nuclear matrix: cellular interpretation of the glycocode
Christopher H. Chay, Kenneth J. Pienta> ;Journal of Cellular Biochemistry. Supplement. 2000 Jan 1
6 citations
Detection of candidates for cancer cell motility inhibitory protein in the Dunning adenocarcinoma model
James L. Mohler, William E. Bakewell, Yousuf Sharief, William B. Coleman, Christopher H. Chay, Scott M. Silver, Gary J. Smith> ;Clinical & Experimental Metastasis. 1995 Nov 1
25 citations
Zea mI, the maize homolog of the allergen-encoding Lol pI gene of rye grass.
Anne Broadwater, Amy L. Rubinstein, Christopher H. Chay, David G. Klapper, Patricia A. Bedinger> ;Gene. 1993 Sep 15
21 citations
Purification of Maize Pollen Exines and Analysis of Associated Proteins
Christopher H. Chay, Erich G. Buehler, Judith M. Thorn, Thomas M. Whelan, Patricia A. Bedinger> ;Plant Physiology. 1992 Oct 1
Join now to see all

Press Mentions

Cancer Clinical Trials As-Care-Option Moves into Western North Carolina via Messino Cancer Centers & Sarah Cannon Research Institute PartnershipNovember 17th, 2020
Messino Cancer Centers Opens in Western North Carolina and Joins the American Oncology Network, LLCJanuary 7th, 2020